ASCO GU 2021: a round up of the latest prostate cancer data

Written by Rachel Jenkins, Future Science Group

ASCO GU

Oncology Central are taking a look at the latest prostate cancer news from ASCO’s Genitourinary Cancers Symposium, which took place virtually on 11–13 February 2021. Find out more below about the final results from the TITAN analysis, the benefit of ipatasertib–abiraterone in metastatic prostate cancer and complementary imaging in staging and localization. Are PSMA PET/CT and mpMRI complementary for staging and localization of prostate cancer? A new single-center study presented at the 2021 Genitourinary Cancers Symposium has compared imaging for the detection and localization of prostate cancer. “The current guidelines recommend the use of cross-sectional imaging, such as CT and...

To view this content, please register now for access

It's completely free